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Abstract
Background Antiretroviral drugs are among the therapeu-
tic agents with the highest potential for drug–drug inter-
actions (DDIs). In the absence of clinical data, DDIs are
mainly predicted based on preclinical data and knowledge
of the disposition of individual drugs. Predictions can be
challenging, especially when antiretroviral drugs induce
and inhibit multiple cytochrome P450 (CYP) isoenzymes
simultaneously.
Methods This study predicted the magnitude of the DDI
between efavirenz, an inducer of CYP3A4 and inhibitor of
CYP2C8, and dual CYP3A4/CYP2C8 substrates
(repaglinide, montelukast, pioglitazone, paclitaxel) using a
physiologically based pharmacokinetic (PBPK) modeling
approach integrating concurrent effects on CYPs. In vitro
data describing the physicochemical properties, absorption,
distribution, metabolism, and elimination of efavirenz and
CYP3A4/CYP2C8 substrates as well as the CYP-inducing
and -inhibitory potential of efavirenz were obtained from
published literature. The data were integrated in a PBPK
model developed using mathematical descriptions of
molecular, physiological, and anatomical processes defin-
ing pharmacokinetics. Plasma drug–concentration profiles
were simulated at steady state in virtual individuals for
each drug given alone or in combination with efavirenz.
The simulated pharmacokinetic parameters of drugs given
alone were compared against existing clinical data. The
effect of efavirenz on CYP was compared with published
DDI data.
Results The predictions indicate that the overall effect of
efavirenz on dual CYP3A4/CYP2C8 substrates is induction
of metabolism. The magnitude of induction tends to be less
pronounced for dual CYP3A4/CYP2C8 substrates with
predominant CYP2C8 metabolism.
Conclusion PBPK modeling constitutes a useful mecha-
nistic approach for the quantitative prediction of DDI
involving simultaneous inducing or inhibitory effects on
multiple CYPs as often encountered with antiretroviral
drugs.
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Key Points
The developed physiologically based
pharmacokinetic model integrating mixed effects on
cytochrome P450 (CYP) isoenzymes represents a
useful tool for the quantitative prediction of drug–
drug interactions (DDIs) involving inhibitory and
inducing effects on multiple CYPs as often
encountered with HIV drugs.
The overall effect of efavirenz on dual CYP3A4/
CYP2C8 substrates is induction of metabolism. The
magnitude of induction tends to be less pronounced
for dual CYP3A4/CYP2C8 substrates with
predominant CYP2C8 metabolism.
Dosage adjustments can be simulated to overcome a
given interaction. Thus, this model has the potential
to provide guidance on how to manage DDIs for
drug combinations used in clinical practice for which
no clinical data are available.
1 Introduction
Antiretroviral agents are among the therapeutic agents with
the highest potential for drug–drug interactions (DDIs),
mainly due to their inhibitory and/or inductive effects on
liver-metabolizing enzymes such as the cytochrome P450
(CYP) isoenzymes and drug transporters [1, 2]. Studies
assessing the prevalence of DDIs with HIV therapy have
indeed shown that potential clinically significant DDIs are
common, affecting 19–41 % of HIV-infected patients
[3–7]. The problem of DDIs is likely to worsen with an
aging HIV patient population where multiple treatments for
co-morbidities may interact with HIV therapy [8]. DDIs
may be associated with a substantial risk for toxicity or
decreased efficacy and therefore the management of DDIs
is crucial for the care of HIV-infected patients.
One of the current issues related to DDIs is the limited
availability of clinical data on DDIs between antiretroviral
drugs and commonly prescribed drugs in HIV patients. In
the absence of clinical data, potential clinically relevant
DDIs are predicted based on in vitro experimental data
which may not correctly reflect the in vivo drug metabo-
lism (especially if these data are not considered in models
to predict DDI). For instance, the contribution of a given
CYP to the overall metabolic clearance (CL) is not always
scaled to the hepatic CYP expression. In addition, the
concentrations of drug substrates and inhibitors/inducers
used in vitro may not always reflect the therapeutic con-
centrations to which CYP are exposed. Finally, these
experimental data do not incorporate the concurrent inhi-
bitory and inducing effects on CYPs. Therefore, the net
effect of a DDI can be difficult to predict, particularly for
drugs whose metabolism can be simultaneously induced
and inhibited by a given DDI perpetrator.
Efavirenz, a first-generation non-nucleoside reverse
transcriptase inhibitor, is a well-known perpetrator of
DDIs. Efavirenz is primarily metabolized by CYP2B6 to
8-hydroxy-efavirenz (8-hydroxy-EFV), secondarily by
CYP2A6 to 7-hydroxy-efavirenz (7-hydroxy-EFV) and by
uridine 5’-diphospho-glucuronosyltransferase (UGT) 2B7
[9, 10]. Efavirenz has been shown to be an inducer of
CYP3A4 and CYP2B6 in vivo [11, 12] but also an inhibitor
of CYP2C8 in vitro [13]. The clinical relevance of
CYP2C8 inhibition by efavirenz has also been demon-
strated in a report describing an increase in amodiaquine
exposure, a CYP2C8 substrate, and related hepatotoxicity
during co-administration with efavirenz in healthy volun-
teers [14]. The net effect of efavirenz on dual CYP3A4/
CYP2C8 substrates is currently unknown and difficult to
predict when considering in vitro drug metabolism data
alone.
Physiologically based pharmacokinetic (PBPK) model-
ing has emerged as a performant tool in recent years for
prediction of CYP-mediated DDIs [15, 16]. This approach
enables the simulation of the pharmacokinetics of a drug
using in vitro drug data (i.e., physicochemical character-
istics, intrinsic CL [CLint], permeability) through a math-
ematical description of absorption, distribution,
metabolism, and elimination (ADME) of a drug. The
in vitro CLint is usually quantified using recombinant CYPs
and subsequently scaled up to determine the hepatic CL by
considering factors such as CYP abundance in microsomal
protein, microsomal protein per gram of liver, liver weight,
blood flow, and protein binding. The magnitude of a DDI is
simulated using data from in vitro studies investigating the
potential of a given drug to inhibit or induce CYPs. These
data are subsequently integrated in the equations describing
reverse or time-dependent inhibition or induction. The
PBPK modeling approach presents the advantage of inte-
grating the fraction of the drug metabolized by a given
CYP and the effect of concurrent inhibition and induction
of multiple CYPs. In addition, this approach incorporates
gut metabolism (Fg) and the temporal changes in the
concentration of the perpetrator and victim drugs and
therefore predicts DDI in a more comprehensive and
meaningful way [17]. Finally, PBPK models can be applied
to simulate clinical scenarios in relation to DDIs to provide
guidance on how to manage DDIs for drug combinations
used in clinical practice but for which limited clinical data
are available [18, 19].
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The aim of this study was to develop PBPK models
integrating concurrent inducing and inhibitory effects to
simulate the magnitude of DDIs between efavirenz and
dual CYP3A4/CYP2C8 substrates with distinct contribu-
tions of CYP3A4 versus CYP2C8 to their overall meta-
bolism. The models were first applied to simulate the
pharmacokinetics of individual drugs and validated
against available clinical data to evaluate their predictive
performance. The models were subsequently used to
simulate virtual DDI trials to determine the magnitude of
DDIs and the potential dose adjustments to overcome the
effect of efavirenz on various dual CYP3A4/CYP2C8
substrates.
2 Methods
2.1 Parameters of Physiologically Based
Pharmacokinetic (PBPK) Models
The PBPK models were designed using Simbiology ver-
sion 4.3.1, a product of MATLAB version 8.2 (Math-
Works, Natick, MA, USA; 2013). The main parameters of
the models are described following.
2.1.1 Virtual Individuals
Virtual individuals were generated using a population
physiology model (physB) which compiles a statistical
description of the physiological and anatomical parameters
representing the general adult population (age range of
18–60 years with a mean age of 36.5 ± 13 years) [20].
Age, body surface area, body mass index, weight, and
height were used to allometrically scale organ and tissue
weights. The blood circulation took into account the car-
diac output and the regional blood flows to the organs as
previously described [20].
2.1.2 Oral Absorption
Oral absorption was simulated using a compartmental
absorption and transit model and considering a stomach
transit time of 0.5 h and a small intestine transit time of
3.3 h as previously reported [21]. The absorption rate
constant (ka) of drugs was derived from the effective per-
meability (Peff) obtained from published Caco-2 cells or,
when these data were not available, from polar surface area
and hydrogen bond donor experimental data as previously
described [22]. The absorption model does not handle a
solid dosage form and therefore assumes no limitation from
solubility.
2.1.3 Intestinal Metabolism
The CL of drugs in the gut (CLg) was determined by
considering the abundance of CYP3A in the intestinal tis-
sue (AbCYP3A) and the in vitro CLint as described pre-
viously [22, 23]. The CLg did not incorporate efavirenz
induction effect on intestinal CYP3A since in vivo studies
have shown that efavirenz does not induce intestinal
enzymes or transporters [12, 24]. The well-stirred gut
model, assuming instant distribution of the drug to the
enterocytes, was used to determine the amount of drug
escaping Fg and reaching the liver using the following
equation (Eq. 1) (it is of note that comparable Fg values
were obtained when using the Qgut model):
Fg ¼ Qg
Qg þ fu;g  CLg ; ð1Þ
where Qg and fu,g represent the blood flow to the gut and
the fraction of the drug unbound in the gut, respectively.
2.1.4 Hepatic Metabolism
The total CLint (TotCLint) of a given CYP in the liver was
determined by considering the in vitro CLint, the amount of
CYP (AbCYP) present in a milligram of microsomal pro-
tein per gram liver (MPPGL), and the liver weight as
described previously [23]. The following equation (Eq. 2)
was used to calculate the age-related values of MPPGL as
previously reported by Barter et al. [25]:
MPPGL ¼ 101:407þ 0:0158Age 0:00038Age2þ 0:0000024Age3:
ð2Þ
Efavirenz induction (Ind) and inhibition (Inh) of liver
enzymes was integrated in the calculation of individual
TotCLint using the following equations (Eqs. 3 and 4):
Ind ¼ 1 þ Emax  Ih
EC50 þ Ih ; ð3Þ
Inh ¼ 1 þ Ih
Ki
; ð4Þ
where Emax, EC50, Ki, and Ih represent the maximum
induction (net maximum fold increase), concentration of
inducer producing 50 % of Emax, concentration of inhibitor
producing 50 % of maximum inhibition, and the concen-
tration of inducer/inhibitor in the liver tissue, respectively.
The total liver CLint (CLliver) was subsequently calcu-
lated as the sum of all the TotCLint of enzymes contributing
to the metabolism of a given drug as described previously
[22]. Finally, the systemic CL was determined taking into
account the blood flow to the liver (Qh) as detailed there-
after (Eq. 5):
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CL ¼ Qh  fu  CLliver
Qh þ fu  CLliver ; ð5Þ
where fu is the fraction unbound in blood.
The amount of drug escaping hepatic metabolism (Fh)
and reaching the systemic circulation was computed using
the following equation (Eq. 6):
Fh ¼ Qh
Qh þ fu  CLliver : ð6Þ
2.1.5 Distribution
The volume of distribution was simulated by calculating
the tissue to plasma partition coefficient for each organ and
considering organ volumes originated from physB using
previously published equations [26, 27].
2.1.6 Intravenous Drug Administration
A compartment was created for the intravenous drug
administration in order to simulate the direct release of the
drug in the arterial compartment. The release rate was set
to reach complete administration of the drug in 2 h in order
to reflect the perfusion time.
2.2 Parameters of Simulated Drugs
PBPK models were developed using published in vitro data
for the following compounds: efavirenz (DDI perpetrator),
the dual CYP3A4/CYP2C8 substrates repaglinide, mon-
telukast, pioglitazone, and paclitaxel, and the CYP3A4
substrate maraviroc to validate efavirenz inducing effect
on CYP3A4.
The in vitro data describing the physicochemical
parameters and the metabolism of the drugs by different
recombinant enzyme isoforms are summarized in Table 1.
Efavirenz is mainly hydroxylated to 8-hydroxy-EFV by
CYP2B6 and to a lesser extent by CYP2A6, CYP1A2,
CYP3A4, and CYP3A5. The conversion to 7-hydroxy-EFV
by CYP2A6 and glucuronidation by UGT2B7 represents
minor pathways [9, 10]. Efavirenz induces CYP3A4 and
CYP2B6 [18] and inhibits CYP2C8, CYP2C9, and
CYP3A4 [13]. CYP3A4/CYP2C8 substrates were selected
to have a distinct contribution of CYP3A4 versus CYP2C8
to their overall metabolism based on in vitro drug meta-
bolism data. The antidiabetic repaglinide is metabolized
equally by CYP3A4 and CYP2C8 [28]; the bronchodilator
montelukast and the antidiabetic pioglitazone are metabo-
lized to a larger extent by CYP2C8 than by CYP3A4
[29, 30]; and the anticancer agent paclitaxel is metabolized
primarily by CYP2C8 with a minor contribution of
CYP3A4 [31]. The minor contribution of CYP2C9 to
montelukast metabolism and the inhibitory effect of
efavirenz on CYP2C9 were also integrated in the mon-
telukast PBPK model. None of the evaluated CYP3A4/
CYP2C8 substrates have clinically relevant inhibitory or
inducing effects on CYPs and therefore are not expected to
impact efavirenz. The antiretroviral agent maraviroc, a
substrate of CYP3A4 devoid of inhibitory or inducing
effects on CYPs, was selected to validate the strength of
CYP3A4 induction by efavirenz [32]. Repaglinide, pacli-
taxel, and maraviroc are substrates of the hepatic transport
organic anion-transporting polypeptide (OATP) 1B1
[33–35]; however, this transporter was not integrated in the
models since efavirenz has been shown to have no effect on
OATP1B1 [24]. Finally, all drugs considered in this study
are extensively metabolized in the liver and therefore no
renal CL component was included in the simulations.
2.3 Validation of PBPK Models
In order to assess and validate the models, the simulated
pharmacokinetic profiles of individual drugs were com-
pared against existing clinical data [36–40]. In addition, the
strength of CYP3A4 induction by efavirenz was validated
by comparing the simulated versus observed DDI between
maraviroc and efavirenz [32]. The strength of CYP2C8
inhibition by efavirenz could not be validated due to lim-
ited data from clinical DDI studies.
2.4 Design of Virtual Drug–Drug Interaction (DDI)
Studies
The dosage and frequency of administration of the evalu-
ated drugs were selected to reflect clinical practice and data
from clinical studies used to validate the models. Simula-
tions were performed in 50 virtual individuals receiving
oral repaglinide 2 mg three times daily, montelukast 10 mg
once daily, or pioglitazone 15 mg once daily without efa-
virenz for 14 days followed by co-administration with
efavirenz 600 mg once daily for another 14 days. Pacli-
taxel is administered intravenously at a dose of 175 mg/m2
every 3 weeks. Therefore, paclitaxel simulations were
performed by creating a compartment to reflect the intra-
venous drug administration and the dose was multiplied by
the body surface area. Similarly to the other drugs, simu-
lations were performed for paclitaxel alone and in combi-
nation with efavirenz. Additional simulations were
performed to determine dose adjustments of repaglinide,
montelukast, pioglitazone, and paclitaxel to overcome the
DDIs with efavirenz. The criterion for dose adjustments
was to obtain a value of drug exposure as close as possible
to the exposure of the drug administered alone considering
available drug dosages on the market (including the pos-
sibility to split a tablet as for pioglitazone) in order to
provide realistic dosage adjustments.
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The pharmacokinetic parameters of the simulations were
presented as mean ± standard deviation (SD). The area
under the plasma concentration–time curve (AUC) for a
dosing interval (AUCs) and maximum concentration (Cmax)
were evaluated after logarithmic transformation, providing
point estimates and 90 % confidence intervals (CIs) for the
combined/single drug administration ratio.
3 Results
3.1 Validation of the PBPK Models
The pharmacokinetics at steady state were initially simu-
lated for each drug alone in order to evaluate the perfor-
mance of PBPK models. As summarized in Table 2, the
simulated pharmacokinetic parameters of efavirenz,
repaglinide, montelukast, pioglitazone, and paclitaxel were
in good accordance with previously described clinical data.
The models could predict the AUC and Cmax of all drugs
within a twofold difference of the observed corresponding
pharmacokinetic parameters (Fig. 1a, b) and therefore
predictions were within the commonly agreeable limits of
variability for validation considering the variability in the
observed pharmacokinetic parameters of some drugs [41].
Furthermore, the simulated DDI between efavirenz
(600 mg once daily) and the CYP3A4 substrate maraviroc
(100 mg twice daily) gave results comparable to those
described in a clinical trial [32]. The comparison of the
maraviroc AUCs with and without efavirenz gave a geo-
metric mean ratio [GMR] (90 % CI) of 0.36 (0.31–0.68)
for the simulation compared with 0.49 (0.41–0.57) for the
Table 1 Physicochemical and metabolic characteristics of simulated drugs
Parameter Efavirenz Repaglinide Montelukast Pioglitazone Paclitaxel Maraviroc
Physicochemical properties [52, 53]
Molecular weight 315.7 452.6 586.2 356.4 853.9 513.7
Log Po:w 4.6 3.95 7.9 2.3 3.54 2.4 [54]
pKa 10.2 4.19 4.4 5.6 10.36 7.3 [54]
fu 0.015 0.03 0.0018 0.015 0.03 [55] 0.13 [56]
B/P 0.74 0.62 0.65 [29] 1.0 0.5 0.59 [54]
PSA 38.33 78.87 70.42 68.29 221.29 63.05
HBD 1 2 2 1 4 1
Absorption
Caco-2 Papp 2.5 9 10
-6 [18] 26.1 9 10-6 [33] 1.5 9 10-6 [57] 0.36 9 10-6 [58]
Metabolism
CYP1A2 CLint 0.07 [10]
CYP2A6 CLint 0.08 [10]
CYP3A4 CLint 0.007 [10] 1.8 [43] 1.8 [29] 0.3 [39] 0.19 [44] 1.7 [54]
CYP3A5 CLint 0.03 [10]
CYP2B6 CLint 0.55 [10]
CYP2C8 CLint 1.7 [43] 3.6 [29] 0.9 [39] 1.68 [31]
CYP2C9 CLint 0.48 [29]
Elimination
fe [59–64]
CYP inhibition (Ki)
\0.01 0.001 \0.002 Negligible 0.013–0.126 0.08
CYP3A4 40.3 [13]
CYP2C8 4.8 [13]
CYP2C9 19.5 [13]
CYP induction Emax EC50
CYP3A4 6.5 [18] 3.9 [18]
CYP2B6 5.7 [18] 0.8 [18]
B/P blood to plasma drug ratio, CLint intrinsic clearance expressed as lL/min/pmol, CYP cytochrome P450, EC50 concentration of inducer
producing 50 % of maximum induction expressed as lmol/L, Emax maximum induction, fe fraction of drug excreted unchanged in urine, fu
fraction of drug unbound in blood, HBD number of hydrogen bond donors, Ki concentration of inhibitor producing 50 % of maximum inhibition
expressed as lmol/L, log Po:w partition coefficient between octanol and water, Papp drug permeability from apical to basolateral in Caco-2 cell
monolayer (10-6 cm/s), pKa acid dissociation constant, PSA polar surface area
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observed clinical data. Similarly, comparison of the mar-
aviroc Cmax with and without efavirenz gave a GMR of
0.39 (0.34–0.44) for the simulation compared with 0.43
(0.30–0.62) for the observed data, indicating that the
strength of CYP3A4 induction by efavirenz was relatively
well-represented by the PBPK models.
3.2 Simulations of DDIs between Efavirenz
and Cytochrome P450 (CYP) 3A4/CYP2C8
Substrates
The simulated DDIs between efavirenz and CYP3A4/
CYP2C8 substrates are presented as GMR (90 % CI) of the
AUCs and Cmax for the combined/single drug administra-
tion ratio (Table 3). These data were further dissected to
look at the effect of efavirenz on the systemic CL,
intestinal metabolism (Fg) and hepatic metabolism Fh of
individual CYP3A4/CYP2C8 substrates.
The simulation of repaglinide plasma profile at a dose of
2 mg three times daily was characterized by a mean
bioavailability of 0.70 (Table 2) resulting mainly from a low
intestinal metabolism (Fg = 0.98) and a first-pass metabo-
lism (Fh = 0.71. The systemic CL was equal to 43 L/h, with
CYP3A4 and CYP2C8 contributing to 80 and 20 % of the
overall systemic CL, respectively. Efavirenz concurrent
induction of CYP3A4 and inhibition of CYP2C8 caused an
overall inducing effect on repaglinide exposure with a sub-
stantial effect on Fh and systemic CL. Efavirenz increased
repaglinide hepatic metabolism by 40 % (Fh decreased from
0.71 to 0.43) and CL increased to 77 L/h. This had a major
effect on repaglinide pharmacokinetics, reducing AUCs by
65 % and Cmax by 60 % (Table 3). Efavirenz had no effect
on Fg. Dose adjustment simulations showed that a dose of
repaglinide 5 mg three times daily resulted in a mean (±SD)
AUC of 65 ± 54 (observed repaglinide AUC when admin-
istered alone at 2 mg three times daily: 69 ± 78), which was
sufficient to overcome the effect of efavirenz on repaglinide
exposure (Table 3; Fig. 2a).
The simulation of montelukast (10 mg once daily)
pharmacokinetics gave a mean bioavailability of 0.81 as a
result of 16 % of the dose not absorbed (fraction absorbed
[Fa] = 0.84), low intestinal metabolism (Fg = 0.99) and
low hepatic metabolism (Fh = 0.97). Montelukast is a low
hepatic extraction drug with an estimated systemic CL
equal to 4.8 L/h that is mediated by CYP3A4 (3.2 L/h),
CYP2C8 (1.4 L/h), and CYP2C9 (0.2 L/h). Efavirenz
concurrent induction of CYP3A4 and inhibition of
CYP2C8 and CYP2C9 caused an overall reduction of
montelukast AUCs and Cmax by 40 and 23 %, respectively
(Table 3). Efavirenz had a modest effect on Fh (5 %
reduction from 0.97 to 0.92), as expected for low hepatic
extraction drugs. Co-administration with efavirenz
increased CL to 12.1 L/h mainly by increasing CYP3A4
CL to 11.8 L/h, whereas CL by CYP2C8 and CYP2C9
were reduced to 0.2 and 0.1 L/h, respectively. A dose
increase to montelukast 14 mg once daily resulted in a
Table 2 Validation of
physiologically based
pharmacokinetic models:
simulated versus observed
clinical data from the literature
Drug AUCs (ng  h/mL) Cmax (ng/mL) F (%) CL (L/h) Vd (L) References
Efavirenz 600 mg od
Simulated 88,153 ± 40,674 5631 ± 1703 73 6.8 ± 2.5a 67 ± 10b [36, 65]
Observed 57,592 ± 22,849 4037 ± 1158 NA 9.4a 252b
Repaglinide 2 mg tid
Simulated 55 ± 27 20.3 ± 7.3 70 43 ± 11 29 ± 4 [37, 59]
Observed 69 ± 78 47.9 ± 32.0 62.5 38 ± 16 31 ± 12
Montelukast 10 mg od
Simulated 2781 ± 914 352 ± 60 81 4.8 ± 1.3 14 ± 1.4 [38, 66]
Observed 3940 ± 880 470 ± 120 66 2.7 10.5
Pioglitazone 15 mg od
Simulated 3281 ± 1161 488 ± 72 92 5.0 ± 1.4a 19.0 ± 1.5b [39, 61]
Observed 5020 ± 1070 597 ± 115 [80 5–7a 17.5b
Paclitaxel 175 mg/m2 iv
Simulated 18,895 ± 7015 4680 ± 730 100 38 ± 11 38 ± 5 [40, 67]
Observed 16,045 (21 %) 3980 (35 %) 100 21.2 137
Data are given as arithmetic mean ± SD or geometric mean (% coefficient of variation)
AUCs area under the plasma concentration–time curve over a dosing interval, CL clearance, Cmax maximum
plasma concentration, F absolute bioavailability, iv intravenous administration, NA not available, od once
daily, tid three times daily, Vd volume of distribution for an adult body weight of 70 kg
a Apparent clearance (CL/F)
b Apparent volume of distribution (Vd/F)
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mean AUC of 2293 ± 980 (observed montelukast AUC
when administered alone at 10 mg once daily:
3940 ± 880), which was sufficient to overcome the efa-
virenz effect on montelukast exposure (Table 3; Fig. 2b).
The simulated pharmacokinetics of pioglitazone
(15 mg once daily) gave a mean total systemic CL of
4.5 L/h, which was mediated by CYP3A4 (2.7 L/h) and
CYP2C8 (1.8 L/h). The bioavailability was equal to 0.92
and resulted from a good absorption of the drug
(Fa = 0.96), minimal Fg (0.99), and low Fh (0.96). Efa-
virenz induction of CYP3A4 increased its CL to 11.6 L/h
while the inhibitory effect on CYP2C8 reduced its CL to
0.26 L/h, which resulted in a mean total systemic CL
equal to 11.9 L/h. The overall effect was a reduction of
pioglitazone AUCs and Cmax by 45 and 27 %, respectively
(Table 3). Efavirenz had a minor effect on Fh with a 6 %
reduction in Fh (from 0.96 to 0.90). A dose increase to
pioglitazone 22.5 mg once daily (representing 1.5 tablets
dosed at 15 mg) resulted in a mean AUC of 3170 ± 1635
(observed pioglitazone AUC when administered alone at
15 mg once daily: 5020 ± 1070), which was sufficient to
overcome the effect of efavirenz on pioglitazone exposure
(Table 3; Fig. 2c).
Paclitaxel (175 mg/m2) total CL was simulated as being
38 L/h, with CYP3A4- and CYP2C8-mediated metabolism
contributing to 30 and 70 % of the overall systemic CL,
respectively. Efavirenz concurrent induction of CYP3A4
and inhibition of CYP2C8 caused a modest change in
paclitaxel exposure with a 14 % decrease in AUCs and 9 %
reduction in Cmax (Table 3). Efavirenz increased total CL
to 54 L/h and the Fh of paclitaxel by 17 %. Given the small
magnitude of the interaction with efavirenz, no dosage
adjustment was required for paclitaxel when co-adminis-
tered with efavirenz (Table 3; Fig. 2d).
4 Discussion
The management of DDIs remains an important aspect of
the care of HIV-infected patients. Due to the limited
number of clinical DDI studies between antiretroviral
drugs and commonly prescribed co-medications, DDIs are
often predicted based on the metabolic pathway of indi-
vidual drugs. However, predictions can be difficult, par-
ticularly when DDI perpetrators are simultaneously
inducing and inhibiting multiple CYPs. The PBPK mod-
eling approach was used to predict the magnitude of DDIs
between efavirenz, an inducer of CYP3A4 and inhibitor of
CYP2C8, and several dual CYP3A4/CYP2C8 substrates.
PBPK models were developed to include the contribu-
tion of each individual CYP to the overall metabolic CL of
the drug and subsequently scaled to their hepatic expres-
sion. For CYP2C8, scaling to the hepatic content consid-
ered a mean CYP2C8 protein expression of 31 ± 18 pmol/
mg as previously described [42] and the fact that CYP2C8
accounts for 6–7 % of the total hepatic CYP content.
Furthermore, the models integrated the simultaneous
inducing and inhibitory effects on CYP3A4 and CYP2C8
as well as the temporal changes in the concentration of
efavirenz and the dual CYP3A4/CYP2C8 substrates in
order to best reflect the in vivo situation. The developed
models were able to predict correctly the pharmacokinetic
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Fig. 1 Scatter plots representing the simulated versus observed area
under the plasma concentration–time curve over a dosing interval
(AUCs) (a) and maximum concentration (Cmax) (b) for all drugs
evaluated in the study. The simulated values represent the mean value
of 50 simulations obtained at steady-state administration for repaglin-
ide 2 mg three times daily; montelukast 10 mg once daily; pioglita-
zone 15 mg once daily; paclitaxel 175 mg/m2; maraviroc 100 mg
twice daily; and efavirenz 600 mg once daily given alone. The dashed
lines represent a twofold difference from the observed pharmacoki-
netic parameters
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parameters of individual drugs. The simulations showed
that the net effect of efavirenz on dual CYP3A4/CYP2C8
substrates was induction of metabolism, which was pre-
dicted to be weak to moderate depending on the contri-
bution of CYP2C8 to the overall metabolic CL as
illustrated for the intermediate hepatic extraction drugs—
repaglinide and paclitaxel. Repaglinide has been shown
in vitro to be equally metabolized by CYP3A4 and
CYP2C8 [43], whereas CYP2C8 is the major contributor of
paclitaxel metabolism [31, 44]. The simulations showed
that the co-administration of efavirenz increased the Fh of
repaglinide by 40 % and only by 17 % for paclitaxel. This
difference can be explained by the lower fraction of
CYP3A4 metabolism being induced by efavirenz in the
case of paclitaxel since CYP2C8 metabolism is the major
contributor of paclitaxel overall Fh, whereas CYP3A4 is
the major contributor of repaglinide metabolism. This
results in paclitaxel total CL being increased from 38 L/h
(without efavirenz) to 54 L/h (with efavirenz), whereas
repaglinide total CL went from 43 L/h (without efavirenz)
to 77 L/h (with efavirenz). Although repaglinide and
paclitaxel are substrates of the hepatic transporter
OATP1B1 [33, 35], this transporter was not included in the
models since in vivo data indicate that it is not impacted by
efavirenz [24]. However, since hepatic uptake by
OATP1B1 is the rate-determining step in the CL of these
drugs and since the transporter capacity can be saturated,
we cannot exclude that induction might have been over-
predicted by not including OATP1B1 in our models.
Clinical data from DDI studies have shown that DDIs
with repaglinide can be complex. For instance, rifampicin
(rifampin), a strong inducer of CYP3A4 and to a lesser
extent of CYP2C8, but also an inhibitor of OATP1B1, was
shown to reduce the repaglinide AUC by 50 % when
administered simultaneously. However, when repaglinide
was given 24 h after the last rifampicin dose, the
repaglinide AUC decreased by 80 % [45]. The lower
magnitude of the DDI observed for the simultaneous
administration of drugs has been attributed to the con-
comitant inhibitory effect of rifampicin on OATP1B1,
which limits the amount of repaglinide entering the liver
and subsequently being induced by CYP3A4. However,
when repaglinide was given 24 h after rifampicin, the
inhibitory effect on OATP1B1 was no longer present and
therefore the DDIs reflected only the inducing effect on
CYPs [45]. Efavirenz has no limiting effect on the entry of
repaglinide in the liver, which could explain that the sim-
ulated induction of repaglinide is comparable with the one
observed when repaglinide is given simultaneously to
rifampicin even though efavirenz is a less potent inducer of
CYPs. Few clinical DDI studies are available for pacli-
taxel; however, data have shown that co-administration
with the strong CYP3A4 inhibitor ketoconazole did not
impact paclitaxel exposure [46]. This observation is con-
sistent with our simulation showing a minimal effect of
efavirenz on paclitaxel exposure. Our simulation also
suggest that the efavirenz inducing effect on CYP3A4 is
stronger than the inhibitory effect on CYP2C8; although
paclitaxel was predominantly cleared by CYP2C8, its
exposure was not increased by efavirenz. The assumption
of a moderate inhibitory effect of efavirenz on CYP2C8 is
consistent with a report indicating that concomitant use of
efavirenz increased amiodaquine exposure by twofold in
one patient and fourfold in another patient [14]. As a
Table 3 Simulated magnitude
of drug–drug interactions
between efavirenz and
cytochrome P450 3A4/2C8
substrates and dosage
adjustments to overcome the
interaction with efavirenz
Parameter AUCs GMR (90 % CI) Cmax GMR (90 % CI)
Repaglinide (2 mg tid) ? EFV
Repaglinide (2 mg tid) alone
0.35 (0.30–0.42) 0.40 (0.35–0.46)
Repaglinide (5 mg tid) ? EFV
Repaglinide (2 mg tid) alone
1.01 (0.83–1.20) 1.11 (0.95–1.29)
Montelukast (10 mg od) ? EFV
Montelukast (10 mg od) alone
0.60 (0.53–0.68) 0.77 (0.72–0.82)
Montelukast (14 mg od) ? EFV
Montelukast (10 mg tid) alone
0.79 (0.70–0.89) 1.07 (1.00–1.14)
Pioglitazone (15 mg od) ? EFV
Pioglitazone (15 mg od) alone
0.55 (0.48–0.63) 0.73 (0.68–0.77)
Pioglitazone (22.5 mg od) ? EFV
Pioglitazone (15 mg od) alone
0.91 (0.81–1.05) 1.15 (1.07–1.23)
Paclitaxel (175 mg/m2) ? EFV
Paclitaxel (175 mg/m2) alone
0.86 (0.76–0.96) 0.91 (0.86–0.96)
AUCs area under the plasma concentration–time curve over a dosing interval, CI confidence interval, Cmax
maximum plasma concentration, EFV efavirenz, GMR geometric mean ratio, od once daily, tid three times
daily
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comparison, the strong CYP2C8 inhibitor gemfibrozil is
predicted to increase the exposure of amiodarone, a drug
exclusively metabolized by CYP2C8, by[15-fold [47].
In vitro studies have shown that montelukast and
pioglitazone are mainly metabolized by CYP2C8 [29, 39].
This has been corroborated by data from clinical DDI
studies showing that gemfibrozil increased montelukast
exposure by fivefold [48] as a result of CYP2C8 inhibition
only since montelukast is not transported by OATP1B1
[49]. Inhibition of CYP3A4 has led to discordant results as
itraconazole was shown to have no significant effect on
montelukast exposure [49], whereas clarithromycin was
shown to increase montelukast exposure by 2.4-fold in
volunteers [38]. Our simulation showed that efavirenz
reduced montelukast exposure, suggesting an effect on
CYP3A4. Finally, available clinical DDI studies for
pioglitazone showed that rifampicin reduced the pioglita-
zone AUC by 54 % [50]. Similarly, our simulation showed
a reduced pioglitazone exposure although, comparative to
rifampicin, the magnitude of the efavirenz effect might be
slightly overestimated as our models were shown to pro-
duce a more pronounced inducing effect on the AUC when
looking at the efavirenz–maraviroc DDI. The stronger
induction of CYP3A4 in our model could be explained by
the higher simulated versus observed efavirenz AUC.
Several limitations to our modeling approach should be
acknowledged. The strength of efavirenz CYP2C8 inhibi-
tion could not be validated due to limited data from clinical
DDI studies. Furthermore, the exact role of CYP2C8 in the
observed DDIs is difficult to determine since available DDI
studies were performed with no fully selective in vivo
inhibitors or inducers of CYP2C8 (i.e., rifampicin,
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Fig. 2 Simulated steady-state plasma profile of repaglinide (a),
montelukast (b), pioglitazone (c), and paclitaxel (d) administered
alone (black profile) and together with multiple doses of efavirenz
(orange profile). The plasma profile after adjustment of the dosage to
overcome the interaction with efavirenz is represented in grey.
Predicted profiles are represented as mean ± standard deviation. The
dashed lines represent the observed plasma profiles of repaglinide
2 mg three times daily [37], montelukast 10 mg once daily [38],
pioglitazone 15 mg once daily [39], and paclitaxel 175 mg/m2 [40].
EFV efavirenz, QD once daily, TID three times daily
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gemfibrozil). Furthermore, all evaluated CYP2C8 sub-
strates in previous clinical studies were partially metabo-
lized by other enzymes or were substrates of OATP1B1,
further complicating the interpretation of DDI studies.
Also, our models did not take into account the effect of
genetic variations on CYP2C8 activity, which may also
have an impact on the magnitude of DDIs [51]. Finally, our
models did not incorporate the physiological changes
related to aging and therefore the magnitude of the simu-
lated DDI does not reflect what might be observed in
elderly patients.
5 Conclusion
The developed PBPK models were able to predict the
pharmacokinetics of efavirenz and dual CYP3A4/CYP2C8
substrates. Furthermore, the models, integrating mixed
effects on CYPs, showed that the net effect of efavirenz on
dual CYP3A4/CYP2C8 substrates was induction of meta-
bolism. However, the magnitude of induction tended to be
less pronounced for dual CYP3A4/CYP2C8 substrates with
predominant CYP2C8 metabolism, which was explained
by a lower fraction of CYP3A4 metabolism being induced
by efavirenz. The PBPK modeling approach constitutes a
useful mechanistic approach for the quantitative prediction
of DDIs. This approach is of particular interest for the
management of DDIs with HIV therapy given that several
antiretroviral drugs are characterized by concurrent
inducing and inhibitory effects on CYPs (i.e., darunavir/
ritonavir, lopinavir/ritonavir, tipranavir/ritonavir), which
makes prediction of DDIs difficult, especially in the con-
text of an aging, poly-medicated HIV population. Impor-
tantly, this approach can be applied to simulate a virtual
clinical study scenario in order to characterize DDIs for
drug combinations used in daily clinical practice but for
which limited clinical data are available, and thus might be
useful in providing guidance on how to manage DDIs.
Other applications of great clinical interest for HIV therapy
include the use of PBPK modeling to predict the pharma-
cokinetics in special populations such as the elderly, chil-
dren, or pregnant women by developing models that
integrate the physiological changes related to these con-
ditions and thus optimize the treatment strategies.
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